



ELSEVIER

Contents lists available at [SciVerse ScienceDirect](#)

Psychiatry Research

journal homepage: www.elsevier.com/locate/psychres

A possible association between panic disorder and a polymorphism in the preproghrelin gene

Caroline Hansson^{a,*}, Kristina Annerbrink^b, Staffan Nilsson^c, Jessica Bah^b, Marie Olsson^b, Christer Allgulander^d, Sven Andersch^e, Ingemar Sjödin^f, Elias Eriksson^b, Suzanne L. Dickson^a

^a Department of Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

^b Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

^c Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden

^d Karolinska Institutet, The Department of Clinical Neuroscience, Section of Psychiatry, Stockholm, Sweden

^e Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

^f Psychiatry Section, Department of Neuroscience and Locomotion, Linköping University, Linköping, Sweden

ARTICLE INFO

Article history:

Received 12 January 2012

Received in revised form

22 August 2012

Accepted 27 September 2012

Keywords:

Ghrelin

Obestatin

SNP

Anxiety

rs4684677

Gln90Leu

Panic disorder

ABSTRACT

The aim of the study was to investigate whether polymorphisms in the preproghrelin gene are associated with anxiety disorders, such as panic disorder, in humans. Panic disorder is a severe anxiety disorder, characterized by sudden attacks of intense fear or anxiety in combination with somatic symptoms. The preproghrelin gene codes for two gut-derived circulating peptides that have been linked to anxiety-like behaviour in rodents: ghrelin (an orexigenic, pro-obesity hormone) and obestatin. In the present study, we genotyped three missense mutations in the preproghrelin gene in 215 patients suffering from panic disorder and in 451 controls. The A allele of the rs4684677 polymorphism was significantly associated with panic disorder, while there were no significant associations with the two other polymorphisms studied. We conclude that the rs4684677 (Gln90Leu) polymorphism in the preproghrelin gene may be associated with increased risk of panic disorder. It will be important to confirm these findings in additional panic disorder patient groups.

© 2012 Elsevier Ireland Ltd. Open access under [CC BY-NC-ND license](#).

1. Introduction

Panic disorder is a severe anxiety disorder, characterized by sudden attacks of intense fear or anxiety, often in combination with physical symptoms such as heart palpitations and shortness of breath (American Psychiatric Association, 2000). Panic disorder has been shown to be hereditary (Hettema et al., 2001), but the genes responsible for the disease still remain to be elucidated. Several genes have been studied in relation to panic disorder. These include genes involved in serotonergic signalling, such as the serotonin transporter, several serotonergic receptors and genes involved in production and degradation of serotonin, but also other genes, such as brain-derived neurotrophic factor (BDNF), angiotensin and genes involved in hormonal systems, such as sex hormones and the hypothalamic-pituitary-adrenal (HPA) axis. These studies have yielded both positive and negative results. The most consistent finding is the association

between panic disorder and a polymorphism in the catechol-O-methyltransferase (COMT) gene (Na et al., 2011).

The preproghrelin gene codes for two circulating peptides, ghrelin (Kojima et al., 1999) and obestatin (Zhang et al., 2005), that are produced predominantly by the stomach. Ghrelin is perhaps best known for its orexigenic (Wren et al., 2000) and adipogenic effects (Tschöp et al., 2000). Interestingly, ghrelin has been shown to affect anxiety-like behaviour in rodents, although both anxiogenic (Asakawa et al., 2001; Carlini et al., 2002, 2004; Hansson et al., 2011; Kanehisa et al., 2006) and anxiolytic (Lutter et al., 2008) effects of ghrelin have been reported. Recently, we performed the first long-term study showing that chronic central infusion of ghrelin to rats increases anxiety-like behaviour (Hansson et al., 2011). We have also shown that gastrectomy, which substantially reduces circulating ghrelin levels, decreases anxiety- and depression-like behaviour in rats (Salome et al., 2011). Obestatin has also been implicated in anxiety-related behaviour but, in contrast to ghrelin, it decreases anxiety-like behaviour in rats (Carlini et al., 2007). Central infusion of antisense against GPR39 (previously thought to be a receptor for obestatin) to rats has also been shown to influence anxiety-like behaviour (Ishitobi et al., 2012). Inspired by the hypothesis

* Corresponding author. Current address: Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy at the University of Gothenburg, Box 425, SE-415 30 Gothenburg, Sweden. Tel.: +46 31 786 6747.

E-mail address: caroline.hansson@gu.se (C. Hansson).

emerging from these animal studies, that peptides derived from the preproghrelin gene may have a role in anxiety behaviour, we have begun to explore the clinical relevance of these findings. Here we sought to determine whether there is an association between panic disorder and polymorphisms in the preproghrelin gene in a Swedish population.

2. Materials and methods

2.1. Experimental design

The preproghrelin gene contains three known exonic polymorphisms, all of which are missense mutations. These are rs4684677, situated in exon 4, implying the amino acid exchange Gln90Leu; rs34911341, located in exon 3, implying the amino acid exchange Arg51Gln; and rs696217, also located in exon 3, and implying the amino acid exchange Leu72Met.

2.2. Subjects

The panic disorder group consisted of 215 patients (63 men and 152 women), meeting the DSM-IV criteria for panic disorder. Their mean age was 43 years (range 15–77 years). All of the patients had panic disorder as the main diagnosis and 83% also suffered from agoraphobia. Patients were screened with diagnostic interview schedules to exclude those with concurrent major depression, psychoses or substance use disorders. The controls were originally collected for a study of obesity, anthropometrics, and cardiovascular risk factors comprising 199 men born in 1944 (51 years old at the time of the assessment) and 252 women born in 1956 (40 years old at the time of the assessment) and living in Gothenburg, Sweden, who were drafted from a larger cohort recruited from the general population as previously described (Rosmond and Bjornorp, 1998; Rosmond et al., 1998). Both patients and controls were Caucasians. These cohorts of patients and controls have been studied previously (Annerbrink et al., 2010; Ho et al., 2004; Olsson et al., 2004). The study was approved by the Research Ethics Committee at the University of Gothenburg. All participants provided written informed consent.

2.3. Genotyping

Venous blood was collected from each subject, and genomic DNA was isolated using the QIAamp DNA blood Mini Kit (Qiagen, Chatsworth, CA, USA). Initially, the polymorphisms were assessed for 175 patients and all controls using sequenom. For the polymorphism rs4684677, the remaining 40 panic disorder patients, as well as samples for which the sequenom analysis failed, were analysed using pyrosequencing. For the polymorphisms rs34911341 and rs696217, these samples were analysed using TaqMan SNP genotyping assays.

2.3.1. Sequenom analysis

Genotyping was performed at Sequenom Inc. in Hamburg, Germany, using the Sequenom iPLEX[®] Gold assay and MassARRAY[®] MALDI-TOF mass spectrometry platform in accordance with the manufacturer's instructions (Sequenom Inc., San Diego, CA). Primers for polymerase chain reaction (PCR) amplification and sequencing were designed using the Sequenom MassARRAY[®] System Designer software.

2.3.2. Pyrosequencing

The following primers were used for pyrosequencing (Ahmadian et al., 2006) (PSQ96 System; Biotage, Uppsala, Sweden) analysis of the rs4684677 polymorphism: forward: 5'-CATGTGGGGCTGCAAGGA-3', reverse: 5'-TCCCTGCCCTGCCTCTA-3', and sequence: 5'-GCTGTGCTGCTGGTA-3'. The DNA was amplified using HotStarTaq Master mix kit (Qiagen), each reaction containing one unit HotStarTaq DNA polymerase, 1.5 mM magnesium chloride, 200 μM of each dNTP, 50 ng genomic DNA and 0.15 μM of each primer, in a total volume of 20 μl. The PCR comprised an initial denaturing step at 95 °C for 15 min, 45 cycles of 95 °C for 15 s, 58 °C for 15 s, and 72 °C for 15 s, followed by a final extension at 72 °C for 7 min. Twenty microlitres of the PCR product was used for the pyrosequencing. Fifteen picomoles of the sequencing primers was used to detect the polymorphism.

2.3.3. TaqMan SNP genotyping

The SNPs rs34911341 and rs696217 were analysed using Applied Biosystems pre-made reagents (C_25607739_20 and C_3151003_20, respectively, Applied Biosystems Inc., Foster City, CA, USA). The assays were performed under recommended conditions on an Applied Biosystems Prisma 7900 HT real-time PCR instrument, using standard reagents from Applied Biosystems.

2.4. Statistical analysis

Hardy–Weinberg equilibrium was checked in the control sample using Haploview. Association between polymorphisms and panic disorder was analysed with logistic regression using the count of the rare allele as numeric predictor. *p*-Values were corrected for multiple testing using permutation tests due to the linkage disequilibrium between the single nucleotide polymorphisms (SNPs).

3. Results

The genotype frequencies in the control sample were in Hardy–Weinberg equilibrium. Clinical data are summarized in Table 1. About 83% of the patients with panic disorder had agoraphobia as a second diagnosis (Table 1). The minor allele frequencies of the three SNPs rs4684677, rs34911341 and rs696217 were, respectively, 0.105, 0.012 and 0.105 in cases and 0.068, 0.004 and 0.099 in controls. The A allele of the rs4684677 polymorphism was significantly associated with panic disorder (odds ratio=1.57, *p*=0.025). No significant associations were found for either of the other two SNPs tested (rs34911341 and rs696217; Table 2).

4. Discussion

The present study supports an association between panic disorder and variations in the preproghrelin gene. We found that the A allele of the rs4684677 T>A polymorphism in the preproghrelin gene is significantly associated with increased risk of panic disorder (OR=1.57). This polymorphism is a missense mutation located in exon 4 and is responsible for an amino acid exchange from Leu to Gln.

The SNP rs4684677 is situated in the part of the preproghrelin gene that codes for obestatin. It is possible therefore that the

Table 1
Clinical data.

	Number of cases	Age (S.D.)	Agoraphobia
<i>Panic disorder</i>	215	43.4 (12.4)	179
Male subsample	63	43.9 (11.4)	47
Female subsample	152	43.2 (13.0)	132
<i>Controls</i>	451	44.9 (5.5)	n.a.
Male subsample	199	51	n.a.
Female subsample	252	40	n.a.

Number of cases: number of subjects in each group, age (S.D.): mean age of each group (standard deviation is given in parentheses), agoraphobia: number of subjects suffering from agoraphobia as the second diagnosis. Numbers are given for cases and controls, and are also further divided into male and female subgroups.

Table 2
Association between panic disorder and SNPs in the preproghrelin gene.

SNP	Genotype	PD	Ctrl	OR	<i>p</i>	<i>p_c</i>	MAF
rs4684677	TT	174 (81%)	393 (87%)	1.57	0.025	0.05	0.068
	AT	37 (17%)	55 (12%)				
	AA	4 (2%)	3 (1%)				
rs34911341	CC	210 (98%)	447 (99%)	2.66	0.148	0.38	0.004
	CT	5 (2%)	4 (1%)				
	TT	0 (0%)	0 (0%)				
rs696217	GG	170 (79%)	367 (81%)	1.07	0.731	0.98	0.099
	GT	45 (21%)	79 (18%)				
	TT	0 (0%)	5 (1%)				

PD: panic disorder (*n*=215), Ctrl: controls (*n*=451), OR: odds ratio per minor allele, *p*: *p*-value using logistic regression, *p_c*: *p*-value corrected for multiple inference by permutation, MAF: minor allele frequency in controls.

association between this SNP and panic disorder is due to variations in the obestatin peptide. Although ghrelin and obestatin are derived from the same gene, they seem to have opposing effects in some important aspects. While ghrelin is orexigenic (Wren et al., 2000), obestatin decreases food intake (Zhang et al., 2005). Moreover, while most studies indicate that ghrelin is anxiogenic (Asakawa et al., 2001; Carlini et al., 2002, 2004; Hansson et al., 2011), obestatin has been shown to decrease anxiety-like behaviour in rats (Carlini et al., 2007).

The polymorphism rs4684677 has previously been studied in relation to alcohol dependence (Landgren et al., 2010), hypertension and atherosclerosis (Berthold et al., 2010), body composition and serum lipids (Martin et al., 2008), adult stature (Gueorguiev et al., 2007), metabolic syndrome (Steinle et al., 2005), and eating disorders (Kindler et al., 2011), but none of these studies showed any significant associations between this polymorphism and the trait studied. The results regarding obesity and this polymorphism are inconclusive. One study found no association between rs4684677 and obesity (Larsen et al., 2005), while this SNP was associated with obesity in two other studies (Gueorguiev et al., 2009; Hinney et al., 2002). Recently, this SNP was studied in relation to panic disorder and major depression in a Japanese cohort, but no significant association was found (Ishii et al., 2009), possibly due to the small number of subjects (138 patients diagnosed with panic disorder and 242 controls). In contrast to our finding, in the Japanese cohort there was a tendency towards fewer mutant alleles in the patients suffering from panic disorder compared to the controls. Genetic differences between Caucasian and Asian subjects may contribute to the discrepant observations and have been reported previously in a study showing an association between panic disorder and a SNP in the COMT gene (Annerbrink et al., 2010). The functional significance of the rs4684677 polymorphism has not been studied.

The rare polymorphism rs34911341 C > T implies the amino acid exchange Arg51Gln. Carriers of the Arg51Gln genotype have significantly lower plasma ghrelin concentrations than Arg51Arg carriers, even when adjusted for fat mass (Ukkola et al., 2002). While this SNP did not show any statistically significant association with panic disorder ($p=0.148$), the odds ratio was still 2.66 and the lack of statistical significance could be due to the fact that the power is clearly lower for such rare mutations (MAF=0.004).

The polymorphism rs696217 G > T, implying the amino acid exchange Leu72Met, is also associated with altered plasma ghrelin levels. Carriers of the Met allele (Met72Met and Leu72-Met) have higher plasma levels of ghrelin than those with the Leu72Leu genotype after adjustment for body-mass index (Ando et al., 2007). Leu72Met (rs696217) has previously been studied in relation to panic disorder, but no significant association was found, which is in line with our results. On the other hand, these authors found a significant association between this polymorphism and major depression (Nakashima et al., 2008). Another study suggested that this polymorphism is associated with anxiety and depression in methamphetamine users, while it is not associated with genetic susceptibility for methamphetamine abuse (Yoon et al., 2005). Polymorphisms in the preproghrelin gene have also been suggested to be associated with bulimia nervosa (Ando et al., 2006) and the drive for thinness and body dissatisfaction (Ando et al., 2007), supporting a role for alterations in the preproghrelin gene with psychiatry-related disorders.

Panic disorder, like most psychiatric disorders, is a complex disorder and polymorphisms in several genes likely contribute to the disease. The serotonin system is probably the most studied candidate, partly because selective serotonin reuptake inhibitors (SSRIs) are first choice treatment for the disease. Accordingly, a polymorphism in the serotonin transporter gene has been shown to be associated with panic disorder (Gyawali et al., 2010). Several serotonergic receptors have also been studied in relation to panic

disorder, including, for example, the serotonin receptor 1A, which is involved in regulating the release of serotonin (Barnes and Sharp, 1999) and has also been implicated in anxiety (Akimova et al., 2009). Several polymorphisms in the serotonin receptor 1A gene, HTR1A, have been shown to be associated with panic disorder (Blaya et al., 2010). One of these is the functional polymorphism -1019C/G, which has previously been shown to be associated with panic disorder with agoraphobia (Rothe et al., 2004).

The most consistent finding in panic disorder genetics is the association between panic disorder and a polymorphism in the COMT gene (Hamilton et al., 2002), which has been replicated several times (Annerbrink et al., 2010; Domschke et al., 2004; Rothe et al., 2006). This polymorphism, Val158Met, strongly influences the enzymatic activity of COMT (Lachman et al., 1996). An interaction between the V158G polymorphism in COMT and the -1019C/G polymorphism in HTR1A has been reported (Freitag et al., 2006) and it would be interesting to investigate how polymorphisms in these and other genes would interact with the finding of the present study.

A limitation of the present study is the small number of study subjects, especially in the panic disorder group. The results of this study should be interpreted with caution as they need to be confirmed in other populations. However, the findings of the present study, taken together with the effects of ghrelin on anxiety-related behaviour in animal studies, suggest that it would be of interest to further investigate the hypothesis that ghrelin could be involved in the pathophysiology of anxiety-related disorders.

We conclude that panic disorder may be associated with a polymorphism in the preproghrelin gene.

Acknowledgements

The Swedish Research Council for Medicine (2009-S266), European Commission 7th Framework (FP7-HEALTH-2009-241592) (EurOCHIP), FP7-KBBE-2009-3-245009 (NeuroFAST) and FP7-KBBE-2010-4-266408 (Full4Health), FOU/ALF Göteborg (ALFGBG-138741) and the Swedish Foundation for Strategic Research to Sahlgrenska Center for Cardiovascular and Metabolic Research (A305-188).

References

- Ahmadian, A., Ehn, M., Hober, S., 2006. Pyrosequencing: history, biochemistry and future. *Clinica Chimica Acta* 363, 83–94.
- Akimova, E., Lanzemberger, R., Kasper, S., 2009. The serotonin-1A receptor in anxiety disorders. *Biological Psychiatry* 66, 627–635.
- American Psychiatric Association, 2000. *Diagnostic and Statistical Manual of Mental Disorders: DSM-IV*, 4th ed. APA, Washington, DC.
- Ando, T., Ichimaru, Y., Konjiki, F., Shoji, M., Komaki, G., 2007. Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women. *American Journal of Clinical Nutrition* 86, 25–32.
- Ando, T., Komaki, G., Naruo, T., Okabe, K., Takii, M., Kawai, K., Konjiki, F., Takei, M., Oka, T., Takeuchi, K., Masuda, A., Ozaki, N., Suematsu, H., Denda, K., Kurokawa, N., Itakura, K., Yamaguchi, C., Kono, M., Suzuki, T., Nakai, Y., Nishizono-Maher, A., Koide, M., Murakami, K., Nagamine, K., Tomita, Y., Ookuma, K., Tomita, K., Tonai, E., Ooshima, A., Ishikawa, T., Ichimaru, Y., 2006. Possible role of preproghrelin gene polymorphisms in susceptibility to bulimia nervosa. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 141B, 929–934.
- Annerbrink, K., Westberg, L., Olsson, M., Allgulander, C., Andersch, S., Sjödin, I., Holm, G., Eriksson, E., 2010. Association between the catechol-O-methyltransferase Val158Met polymorphism and panic disorder: a replication. *Psychiatry Research* 178, 196–198.
- Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Fujimiya, M., Katsuura, G., Makino, S., Fujino, M.A., Kasuga, M., 2001. A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. *Neuroendocrinology* 74, 143–147.
- Barnes, N.M., Sharp, T., 1999. A review of central 5-HT receptors and their function. *Neuropharmacology* 38, 1083–1152.
- Berthold, H.K., Giannakidou, E., Krone, W., Tregouet, D.A., Gouni-Berthold, I., 2010. Influence of ghrelin gene polymorphisms on hypertension and atherosclerotic disease. *Hypertension Research* 33, 155–160.

- Blaya, C., Salum, G.A., Moorjani, P., Seganfredo, A.C., Heldt, E., Leistner-Segal, S., Smoller, J.W., Manfro, G.G., 2010. Panic disorder and serotonergic genes (SLC6A4, HTR1A and HTR2A): association and interaction with childhood trauma and parenting. *Neuroscience Letters* 485, 11–15.
- Carlini, V.P., Monzon, M.E., Varas, M.M., Cragolini, A.B., Schioth, H.B., Scimonelli, T.N., de Barioglio, S.R., 2002. Ghrelin increases anxiety-like behavior and memory retention in rats. *Biochemical and Biophysical Research Communications* 299, 739–743.
- Carlini, V.P., Schioth, H.B., Debarioglio, S.R., 2007. Obestatin improves memory performance and causes anxiolytic effects in rats. *Biochemical and Biophysical Research Communications* 352, 907–912.
- Carlini, V.P., Varas, M.M., Cragolini, A.B., Schioth, H.B., Scimonelli, T.N., de Barioglio, S.R., 2004. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. *Biochemical and Biophysical Research Communications* 313, 635–641.
- Domschke, K., Freitag, C.M., Kuhlbaumer, G., Schirmacher, A., Sand, P., Nyhuis, P., Jacob, C., Fritze, J., Franke, P., Rietschel, M., Garritsen, H.S., Fimmers, R., Nothen, M.M., Lesch, K.P., Stogbauer, F., Deckert, J., 2004. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. *The International Journal of Neuropsychopharmacology* 7, 183–188.
- Freitag, C.M., Domschke, K., Rothe, C., Lee, Y.J., Hohoff, C., Gutknecht, L., Sand, P., Fimmers, R., Lesch, K.P., Deckert, J., 2006. Interaction of serotonergic and noradrenergic gene variants in panic disorder. *Psychiatric Genetics* 16, 59–65.
- Gueorguiev, M., Lecoeur, C., Meyre, D., Benzinou, M., Mein, C.A., Hinney, A., Vatin, V., Weill, J., Heude, B., Hebebrand, J., Grossman, A.B., Korbonits, M., Froguel, P., 2009. Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity. *Obesity (Silver Spring)* 17, 745–754.
- Gueorguiev, M., Wiltshire, S., Garcia, E.A., Mein, C., Lecoeur, C., Kristen, B., Allotey, R., Hattersley, A.T., Walker, M., O'Rahilly, S., Froguel, P., Grossman, A.B., McCarthy, M.L., Hitman, G.A., Korbonits, M., 2007. Examining the candidacy of ghrelin as a gene responsible for variation in adult stature in a United Kingdom population with type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism* 92, 2201–2204.
- Gyawali, S., Subaran, R., Weissman, M.M., Hershkowitz, D., McKenna, M.C., Talati, A., Fyer, A.J., Wickramaratne, P., Adams, P.B., Hodge, S.E., Schmidt, C.J., Bannon, M.J., Glatt, C.E., 2010. Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder. *Biological Psychiatry* 67, 331–338.
- Hamilton, S.P., Slager, S.L., Heiman, G.A., Deng, Z., Haghighi, F., Klein, D.F., Hodge, S.E., Weissman, M.M., Fyer, A.J., Knowles, J.A., 2002. Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. *Biological Psychiatry* 51, 591–601.
- Hansson, C., Haage, D., Taube, M., Egecioglu, E., Salome, N., Dickson, S.L., 2011. Central administration of ghrelin alters emotional responses in rats: behavioural, electrophysiological and molecular evidence. *Neuroscience* 180, 201–211.
- Hettema, J.M., Neale, M.C., Kendler, K.S., 2001. A review and meta-analysis of the genetic epidemiology of anxiety disorders. *American Journal of Psychiatry* 158, 1568–1578.
- Hinney, A., Hoch, A., Geller, F., Schafer, H., Siegfried, W., Goldschmidt, H., Remschmidt, H., Hebebrand, J., 2002. Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. *Journal of Clinical Endocrinology and Metabolism* 87, 2716.
- Ho, H.P., Westberg, L., Annerbrink, K., Olsson, M., Melke, J., Nilsson, S., Baghaei, F., Rosmond, R., Holm, G., Bjorntrorp, P., Andersch, S., Allgulander, C., Eriksson, E., 2004. Association between a functional polymorphism in the progesterone receptor gene and panic disorder in women. *Psychoneuroendocrinology* 29, 1138–1141.
- Ishii, T., Akiyoshi, J., Hanada, H., Ishitobi, Y., Tanaka, Y., Tsuru, J., Matsushita, H., Kodama, K., 2009. Association between the obestatin and BDNF gene polymorphism and panic disorder, and depressive disorder. *Psychiatric Genetics* 19, 159.
- Ishitobi, Y., Akiyoshi, J., Honda, S., Ninomiya, T., Kanehisa, M., Tanaka, Y., Tsuru, J., Isogawa, K., Kitamura, H., Fujikura, Y., 2012. Administration of antisense DNA for GPR39-1b causes anxiolytic-like responses and appetite loss in rats. *Neuroscience Research* 72, 257–262.
- Kanehisa, M., Akiyoshi, J., Kitaichi, T., Matsushita, H., Tanaka, E., Kodama, K., Hanada, H., Isogawa, K., 2006. Administration of antisense DNA for ghrelin causes an antidepressant and anxiolytic response in rats. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 30, 1403–1407.
- Kindler, J., Bailer, U., de Zwaan, M., Fuchs, K., Leisch, F., Grun, B., Strnad, A., Stojanovic, M., Windisch, J., Lennkh-Wolfsberg, C., El-Giamal, N., Sieghart, W., Kasper, H., Aschauer, H., 2011. No association of the neuropeptide Y (Leu7Pro) and ghrelin gene (Arg51Gln, Leu72Met, Gln90Leu) single nucleotide polymorphisms with eating disorders. *Nordic Journal of Psychiatry* 65, 203–207.
- Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., Kangawa, K., 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 402, 656–660.
- Lachman, H.M., Papolos, D.F., Saito, T., Yu, Y.M., Szumlanski, C.L., Weinshilboum, R.M., 1996. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. *Pharmacogenetics* 6, 243–250.
- Landgren, S., Jerlhag, E., Hallman, J., Orelund, L., Lissner, L., Strandhagen, E., Thelle, D.S., Zetterberg, H., Blennow, K., Engel, J.A., 2010. Genetic variation of the ghrelin signaling system in females with severe alcohol dependence. *Alcoholism, Clinical and Experimental Research* 34, 1519–1524.
- Larsen, L.H., Gjesing, A.P., Sorensen, T.I., Hamid, Y.H., Echwald, S.M., Toubro, S., Black, E., Astrup, A., Hansen, T., Pedersen, O., 2005. Mutation analysis of the preproghrelin gene: no association with obesity and type 2 diabetes. *Clinical Biochemistry* 38, 420–424.
- Lutter, M., Sakata, I., Osborne-Lawrence, S., Rovinsky, S.A., Anderson, J.G., Jung, S., Birnbaum, S., Yanagisawa, M., Elmquist, J.K., Nestler, E.J., Zigman, J.M., 2008. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. *Nature Neuroscience* 11, 752–753.
- Martin, G.R., Loreda, J.C., Sun, G., 2008. Lack of association of ghrelin precursor gene variants and percentage body fat or serum lipid profiles. *Obesity (Silver Spring)* 16, 908–912.
- Na, H.R., Kang, E.H., Lee, J.H., Yu, B.H., 2011. The genetic basis of panic disorder. *Journal of Korean Medical Science* 26, 701–710.
- Nakashima, K., Akiyoshi, J., Hatano, K., Hanada, H., Tanaka, Y., Tsuru, J., Matsushita, H., Kodama, K., Isogawa, K., 2008. Ghrelin gene polymorphism is associated with depression, but not panic disorder. *Psychiatric Genetics* 18, 257.
- Olsson, M., Annerbrink, K., Westberg, L., Melke, J., Baghaei, F., Rosmond, R., Holm, G., Andersch, S., Allgulander, C., Eriksson, E., 2004. Angiotensin-related genes in patients with panic disorder. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 127B, 81–84.
- Rosmond, R., Bjorntrorp, P., 1998. Psychiatric ill-health of women and its relationship to obesity and body fat distribution. *Obesity Research* 6, 338–345.
- Rosmond, R., Dallman, M.F., Bjorntrorp, P., 1998. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. *Journal of Clinical Endocrinology and Metabolism* 83, 1853–1859.
- Rothe, C., Gutknecht, L., Freitag, C., Tauber, R., Mossner, R., Franke, P., Fritze, J., Wagner, G., Peikert, G., Wenda, B., Sand, P., Jacob, C., Rietschel, M., Nothen, M.M., Garritsen, H., Fimmers, R., Deckert, J., Lesch, K.P., 2004. Association of a functional 1019C > G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. *The International Journal of Neuropsychopharmacology* 7, 189–192.
- Rothe, C., Koszycki, D., Bradwejn, J., King, N., Deluca, V., Tharmalingam, S., Macciardi, F., Deckert, J., Kennedy, J.L., 2006. Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. *Neuropsychopharmacology* 31, 2237–2242.
- Salome, N., Taube, M., Egecioglu, E., Hansson, C., Stenstrom, B., Chen, D., Andersson, D.R., Georg Kuhn, H., Ohlsson, C., Dickson, S.L., 2011. Gastroenteric alters emotional reactivity in rats: neurobiological mechanisms. *European Journal of Neuroscience* 33, 1685–1695.
- Steinle, N.I., Pollin, T.I., O'Connell, J.R., Mitchell, B.D., Shuldiner, A.R., 2005. Variants in the ghrelin gene are associated with metabolic syndrome in the Old Order Amish. *Journal of Clinical Endocrinology and Metabolism* 90, 6672–6677.
- Tschop, M., Smiley, D.L., Heiman, M.L., 2000. Ghrelin induces adiposity in rodents. *Nature* 407, 908–913.
- Ukkola, O., Ravussin, E., Jacobson, P., Perusse, L., Rankinen, T., Tschop, M., Heiman, M.L., Leon, A.S., Rao, D.C., Skinner, J.S., Wilmore, J.H., Sjostrom, L., Bouchard, C., 2002. Role of ghrelin polymorphisms in obesity based on three different studies. *Obesity Research* 10, 782–791.
- Wren, A.M., Small, C.J., Ward, H.L., Murphy, K.G., Dakin, C.L., Taheri, S., Kennedy, A.R., Roberts, G.H., Morgan, D.G., Ghatei, M.A., Bloom, S.R., 2000. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. *Endocrinology* 141, 4325–4328.
- Yoon, S.J., Pae, C.U., Lee, H., Choi, B., Kim, T.S., Lyoo, I.K., Kwon, D.H., Kim, D.J., 2005. Ghrelin precursor gene polymorphism and methamphetamine dependence in the Korean population. *Neuroscience Research* 53, 391–395.
- Zhang, J.Y., Ren, P.G., Avsian-Kretschmer, O., Luo, C.W., Rauch, R., Klein, C., Hsueh, A.J., 2005. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. *Science* 310, 996–999.